Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Rises By 89.2%

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 679,358 shares, an increase of 89.2% from the January 29th total of 358,994 shares. Currently, 19.5% of the company’s shares are sold short. Based on an average daily volume of 895,841 shares, the days-to-cover ratio is presently 0.8 days. Based on an average daily volume of 895,841 shares, the days-to-cover ratio is presently 0.8 days. Currently, 19.5% of the company’s shares are sold short.

Strata Skin Sciences Stock Performance

NASDAQ SSKN opened at $0.25 on Monday. The company has a debt-to-equity ratio of 10.22, a current ratio of 0.95 and a quick ratio of 0.75. The company has a market cap of $1.47 million, a P/E ratio of -0.09 and a beta of 0.33. The stock has a 50-day moving average of $1.02 and a two-hundred day moving average of $1.46. Strata Skin Sciences has a 1-year low of $0.12 and a 1-year high of $3.86.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SSKN. Wall Street Zen raised shares of Strata Skin Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Strata Skin Sciences in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Strata Skin Sciences

A hedge fund recently raised its stake in Strata Skin Sciences stock. Azzad Asset Management Inc. ADV boosted its holdings in shares of Strata Skin Sciences, Inc. (NASDAQ:SSKN) by 81.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,800 shares of the medical device company’s stock after buying an additional 9,800 shares during the quarter. Azzad Asset Management Inc. ADV owned 0.41% of Strata Skin Sciences worth $45,000 as of its most recent SEC filing. Institutional investors own 32.43% of the company’s stock.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.